The impact of tumor regression grade on long-term survival in locally advanced rectal cancer treated with preoperative chemoradiotherapy
| Autor: | Caglayan Geredeli, Selma Sengiz Erhan, Suleyman Sahin, Mustafa Halil Akboru, Cumhur Demir, Sener Cihan, Nilay Sengul Samanci, Abdullah Sakin, Nurgul Yasar |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male Oncology medicine.medical_specialty Colorectal cancer Locally advanced Relapse free survival Disease-Free Survival 03 medical and health sciences 0302 clinical medicine Internal medicine Long term survival medicine Overall survival Humans Pharmacology (medical) Aged Neoplasm Staging Retrospective Studies Aged 80 and over Tumor Regression Grade Preoperative chemoradiotherapy Rectal Neoplasms business.industry Chemoradiotherapy Middle Aged Prognosis medicine.disease Survival Rate 030220 oncology & carcinogenesis Female 030211 gastroenterology & hepatology business Neoadjuvant chemoradiotherapy |
| Zdroj: | Journal of Oncology Pharmacy Practice. 26:1611-1620 |
| ISSN: | 1477-092X 1078-1552 |
| DOI: | 10.1177/1078155219900944 |
| Popis: | PurposeThe aim of this study is to investigate the prognostic effect of tumor regression grade (TRG) on long-term survival in locally advanced rectal cancer treated with preoperative chemoradiotherapy.MethodsMedical records of 182 patients with locally advanced rectal cancer, who were treated with preoperative chemoradiotherapy followed by surgery between 2002 and 2016, were retrospectively reviewed. TRG was classified into five categories based on the pathological response as follows – TRG1: no viable cancer cell, TRG2: single cancer cell or small groups of cancer cells, TRG3: residual tumor outgrown by fibrosis, TRG4: residual tumor outgrowing fibrosis, TRG5: diffuse residual tumor without regression. TRG1, (TRG2+TRG3), and (TRG4+TRG5) were grouped as complete response, intermediate response, and no response, respectively.ResultsOf the 182 patients with locally advanced rectal cancer, 112 (61.5%) were male. The mean age was 54.4 (range, 25–87) years. The total number of patients in complete response, intermediate response, and no response group was 24 (13.2%), 105 (57.7%), and 53 (29.1%), respectively. The corresponding five-year relapse-free survival and overall survival rates were 79.8%–92.3%, 74.7%–79.4%, and 55.7%–55.8%, respectively (p 0.05). In ypStage III patients, relapse-free survival was 62 months in no response group vs. not reached in intermediate response group (p 0.05). In the multivariate analysis, pathological complete response was found to be an independent variable for relapse-free survival and overall survival (hazard ratio (95% confidence interval), 0.34 (0.17–6.77), 0.39 (0.18–0.83), respectively).ConclusionThis study showed that patients with pathological complete response to preoperative chemoradiotherapy had longer relapse-free survival and overall survival rates than those with residual disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|